First-in-Human, Phase I Study of AMT-676 in Patients With Advanced Solid Tumors

Study Identifier:
AMT-676-01
CT.gov Identifier:
NCT06400485
EudraCT Identifier:
N/A
EU Trial (CTIS) Number:
N/A
Study Contact Information:
(210) 593-5651 or [email protected]
Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study will evaluate the Maximum tolerated dose (MTD)/the recommended Phase 2 Dose (RP2D), safety, tolerability, anti-drug activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-676 in Patients with Advanced Solid Tumors.

Mandatory pre-study biopsy sample collection for retrospective immunohistochemistry (IHC) analysis will facilitate a comprehensive exploratory biomarker plan, potentially correlating CDH17 levels with treatment responses.

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Solid Tumor
    • Phase
    The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
    I
    Sex
    Female & Male
    Age
    18+ years
    Study Drug
  • Drug: Experimental: AMT-676 Dose escalation
    • Read More
  • Drug: Treatment: Drugs - AMT-676
  • Drug: Treatment: Drugs: AMT-676
  • Drug: Chinese common name: AMT-676 for injection
  • Drug: AMT-676 will be administered intravenously on a 21-day cycle. The dose escalation will be guided by the Bayesian Optimal Interval (BOIN) design, incorporating an accelerated titration approach to evaluate 6 cohorts: 1.6, 3.2, 4.8, 6.4, 8, and 10 mg/kg.
    • Study Status
    Indicates the current recruitment status or the expanded access status
    Recruiting

    Requirements information
    Inclusion criteria
    • Patients must be willing and able to sign the ICF, and to adhere to the study visit Schedule and other protocol requirements.
    • Age ≥18 years (at the time consent is obtained).
    • Patients with pathologically confirmed unresectable advanced solid tumor. Preferred tumor types include colorectal cancer, gastric cancer, esophageal adenocarcinoma, cholangiocarcinoma, pancreatic ductal cancers, and neuroendocrine tumors.
    • Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy.
    • Patients must have at least one measurable lesion as per RECIST version 1.1.
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
    • Life expectancy ≥3 months.
    • Patients must have adequate organ function
    • Women of child-bearing potential (WCBP) must have a negative serum pregnancy test.
    • Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least 6months after the last dose of the IMP.
    • Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 3 months and 6 months, respectively after the last dose of the IMP.
    • Availability of tumour tissue sample (either an archival specimen or a fresh biopsy material) at screening.
    Exclusion criteria
    • Prior treatment with any agent for the same target or ADC based on topoisomerase I inhibitor.
    • Central nervous system (CNS) metastasis
    • History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
    • Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1.
    • Systemic anti-neoplastic therapy within five half-lives or21 days, whichever is shorter, prior to first dose of the IMP.
    • Radiotherapy to lung field at a total radiation dose of ≥20 Gy within 6 months, wide-field radiotherapy (e.g., >30% of marrow-bearing bones) within 28 days.
    • Major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the IMP, or no recovery from side effects of such intervention.
    • Significant cardiac disease, such as recent (within months prior to first dose of the IMP) myocardial infarction or acute coronary syndromes (including unstable angina pectoris), congestive heart failure (New York Heart Association class III or IV), uncontrolled hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg), uncontrolled cardiac arrhythmias.
    • Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or current ILD/pneumonitis, or suspected ILD/pneumonitis (e.g., idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, etc.) or other lung disease significantly impacting lung function at baseline.
    • History of thromboembolic or cerebrovascular events, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis, or pulmonary emboli within six months prior to first dose of the IMP.
    • Acute and/or clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV)
    • Administration of a live vaccine within 28 days prior to the administration of the first dose of the IMP.
    • Patients requiring concurrent treatment of strong inhibitors or inducers of cytochrome P450 3A4 or 1A2 enzyme (CYP3A or CYP1A2) within 2 weeks prior to the first dose and during the study treatment.
    • Known or suspected severe allergy/hypersensitivity (resulting in treatment discontinuation) to monoclonal antibodies.
    • Known or suspected intolerance to the components of the IMP.
    • Concurrent participation in another investigational therapeutic clinical trial.
    • Patients with known active alcohol or drug abuse.
    • Pregnant or breast-feeding females
    • Mental or medical conditions that prevent the patient from giving informed consent or complying with the trial or other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with the study participation or the IMP administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrolment in this study.
    • Prior history of malignancy other than inclusion diagnosis within five years prior to first dose of the IMP.

    Clinical Study Information for Healthcare Providers

    By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

    View Study Information

    Study Locations

    Location
    Investigator
    Status
    Condition(s) Treated at Site
    Location
    START San Antonio
    San Antonio, TX, United States, 78229
    Investigator
    Drew Rasco
    Status
    Recruiting
    Condition(s) Treated at Site
    Solid Tumor